EGFR and non-small cell lung carcinoma: Furthermore, human clinical trials demonstrated high safety when combining metformin with erlotinib, a tyrosine kinases inhibitor of the epidermal growth factor receptor, in non-diabetic NSCLC patients as a second-line therapy [70].